Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fosun Pharma

- PMLiVE

Merck & Co wins hepatitis C patent dispute with Gilead

US jury upholds claim that Sovaldi and Harvoni infringe two sofosbuvir patents

- PMLiVE

Social media and inflation penalties for generic drugs

US generic drug companies are under more scrutiny as the US public becomes more vocal 

- PMLiVE

A better direction

Could behavioural science be the key to improving patient outcomes?

- PMLiVE

US precision medicine push gathers momentum

Hopes to ‘revolutionise’ medicines through creation of shared healthcare databases

- PMLiVE

The price is right?

To market new innovation against a backdrop of restricted budgets, companies must work hard - and start early

- PMLiVE

Daiichi Sankyo collaborates on e-patient AF resource

Will work with European platform People Who on new illness profile

Daiichi Sankyo logo

Daiichi Sankyo begins sharing clinical trial data online

Joins the likes of GSK, Lilly, UCB and Astellas in opening up its records

12 Challenges Big Pharma Faces in China

Published in eyeforpharma 16 November by Rachel Howard

Research Partnership

China flag thumb

AstraZeneca sets sights on China with Takeda deal

Buys the Japanese firm's respiratory drugs to extends their ongoing biologics R&D collaboration

Daiichi Sankyo logo

Daiichi Sankyo to shut down German antibody unit U3

Will transfer its operations to a research unit in Japan

EISAI

Eisai expands in China with generics company acquisition

BuysLiaoning TianYi Biological Pharmaceutical

Daiichi Sankyo logo

Daiichi Sankyo cuts a swathe through US workforce

Plans to shed upto 1,200 jobs across the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links